Live News Categoriesequity

HUTCHMED (China) Limited (0013.HK) News

Track canonical SquawkNews coverage tagged to 0013.HK, HUTCHMED (China) Limited. This hub brings together deduplicated headlines about hkse, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 1 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol 0013.HK Asset equity Sector Markets 90 days 1 Last 22.54 Updated Sep 24, 2026, 12:01 AM UTC Open live news feed

H HUTCHMED says SAFFRON Phase III trial of savolitinib — osimertinib combo beats chemo in EGFR — mutant NSCLC after osimertinib progression HUTCHMED flagged new data for savolitinib with osimertinib at ESMO Congress 2026 in Madrid on Oct. 23-27. Results will be presented in future oral sessions from two positive Phase III studies, including a Presidential Sy GEOPOLITICS | Sep 24, 2026, 12:01 AM UTC